Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Dilanubicel by Deverra Therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Dilanubicel is under clinical development by Deverra Therapeutics and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...